Description
Experimental and clinical evidence have established the pathophysiological importance of pro-inflammatory pathways in coronary artery disease. Recent data from the PROMINENT, REDUCE-IT, and STRENGTH studies have shown that residual inflammatory risk is strongly associated with recurrent cardiovascular events, cardiovascular death, and all-cause mortality; and clinical trials of anti-inflammatory drugs, the LoDoCo2 and COLCOT studies, have shown reductions in risk of major adverse cardiovascular events in patients with stable atherosclerosis and after recent myocardial infarction. In this basic science webinar, we investigate the role of humoral immunity and IgM antibodies specifically in the progression of atherosclerosis, and inflammation in atherosclerotic events.
